AU2018260666B2 - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea Download PDF

Info

Publication number
AU2018260666B2
AU2018260666B2 AU2018260666A AU2018260666A AU2018260666B2 AU 2018260666 B2 AU2018260666 B2 AU 2018260666B2 AU 2018260666 A AU2018260666 A AU 2018260666A AU 2018260666 A AU2018260666 A AU 2018260666A AU 2018260666 B2 AU2018260666 B2 AU 2018260666B2
Authority
AU
Australia
Prior art keywords
atomoxetine
oxybutynin
receptor antagonist
nri
muscarinic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018260666A
Other languages
English (en)
Other versions
AU2018260666A1 (en
Inventor
Luigi TARANTO-MONTEMURRO
D. Andrew WELLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018260666(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2018260666A1 publication Critical patent/AU2018260666A1/en
Application granted granted Critical
Publication of AU2018260666B2 publication Critical patent/AU2018260666B2/en
Priority to AU2022241471A priority Critical patent/AU2022241471A1/en
Priority to AU2025230729A priority patent/AU2025230729A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018260666A 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea Active AU2018260666B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022241471A AU2022241471A1 (en) 2017-04-28 2022-09-27 Methods and compositions for treating sleep apnea
AU2025230729A AU2025230729A1 (en) 2017-04-28 2025-09-11 Methods and compositions for treating sleep apnea

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US62/491,504 2017-04-28
US201762558814P 2017-09-14 2017-09-14
US62/558,814 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022241471A Division AU2022241471A1 (en) 2017-04-28 2022-09-27 Methods and compositions for treating sleep apnea

Publications (2)

Publication Number Publication Date
AU2018260666A1 AU2018260666A1 (en) 2019-11-14
AU2018260666B2 true AU2018260666B2 (en) 2022-07-21

Family

ID=63918622

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018260666A Active AU2018260666B2 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
AU2022241471A Abandoned AU2022241471A1 (en) 2017-04-28 2022-09-27 Methods and compositions for treating sleep apnea
AU2025230729A Pending AU2025230729A1 (en) 2017-04-28 2025-09-11 Methods and compositions for treating sleep apnea

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022241471A Abandoned AU2022241471A1 (en) 2017-04-28 2022-09-27 Methods and compositions for treating sleep apnea
AU2025230729A Pending AU2025230729A1 (en) 2017-04-28 2025-09-11 Methods and compositions for treating sleep apnea

Country Status (22)

Country Link
US (4) US11123313B2 (enExample)
EP (1) EP3615016A4 (enExample)
JP (3) JP7373997B2 (enExample)
KR (3) KR102682159B1 (enExample)
CN (2) CN110799181A (enExample)
AU (3) AU2018260666B2 (enExample)
BR (1) BR112019022483A2 (enExample)
CA (1) CA3061468A1 (enExample)
CO (1) CO2019013180A2 (enExample)
CR (1) CR20190546A (enExample)
DO (1) DOP2019000274A (enExample)
EC (1) ECSP19084058A (enExample)
GE (4) GEAP202416602A (enExample)
MA (1) MA49069A (enExample)
MX (2) MX394941B (enExample)
MY (1) MY200172A (enExample)
NI (1) NI201900110A (enExample)
PH (1) PH12019502427A1 (enExample)
SG (2) SG10202111623TA (enExample)
UA (1) UA127759C2 (enExample)
WO (1) WO2018200775A1 (enExample)
ZA (1) ZA201907158B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123313B2 (en) * 2017-04-28 2021-09-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
CA3089712A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.
CA3129270A1 (en) 2019-02-08 2020-08-13 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CA3177654A1 (en) 2020-05-05 2021-11-11 Dennis MOLNAR Polymorphic forms of (r)-oxybutynin hydrochloride
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
AU2022231133A1 (en) * 2021-03-04 2023-09-21 Apnimed, Inc. (Delaware) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
US20240189328A1 (en) * 2021-04-16 2024-06-13 Apnimed, Inc. (Delaware) Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
BR112023026158A2 (pt) * 2021-06-17 2024-03-05 Apnimed Inc Delaware Inibidores da recaptação de norepinefrina para tratamento da apneia do sono
CN117956959A (zh) * 2021-08-31 2024-04-30 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CA3259605A1 (en) * 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CA3259602A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea
CN118475347A (zh) 2021-12-22 2024-08-09 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071108A2 (en) 1999-05-20 2000-11-30 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
CN107007602A (zh) * 2011-01-28 2017-08-04 辉达斯医学研究所 治疗阻塞性睡眠呼吸暂停的方法
US11123313B2 (en) * 2017-04-28 2021-09-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
CA3089712A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BART SANGAL R ET AL: "Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness", SLEEP MEDICINE, vol. 9, no. 5, 2008, pg 506 *
TARANTO-MONTEMURRO ET AL., Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility during Non-REM Sleep in Healthy Subjects, AM. J OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 194, no. 7, 2016, pages 878 - 885 *

Also Published As

Publication number Publication date
ZA201907158B (en) 2021-09-29
DOP2019000274A (es) 2019-12-30
US20240261239A1 (en) 2024-08-08
US20200054583A1 (en) 2020-02-20
JP7373997B2 (ja) 2023-11-06
CN110799181A (zh) 2020-02-14
MA49069A (fr) 2020-03-04
KR102682159B1 (ko) 2024-07-08
UA127759C2 (uk) 2023-12-27
ECSP19084058A (es) 2020-01-31
JP2025169279A (ja) 2025-11-12
JP2020517719A (ja) 2020-06-18
KR20190140019A (ko) 2019-12-18
NI201900110A (es) 2020-03-18
SG10202111623TA (en) 2021-12-30
CR20190546A (es) 2020-04-08
CA3061468A1 (en) 2018-11-01
CO2019013180A2 (es) 2020-02-07
GEAP202416602A (en) 2024-10-10
US20240189261A1 (en) 2024-06-13
MX2019012729A (es) 2019-12-19
AU2018260666A1 (en) 2019-11-14
SG11201909973UA (en) 2019-11-28
KR20240042261A (ko) 2024-04-01
GEP20247617B (en) 2024-04-25
WO2018200775A1 (en) 2018-11-01
CN119185558A (zh) 2024-12-27
AU2022241471A1 (en) 2022-10-27
AU2025230729A1 (en) 2025-10-02
GEP20227387B (en) 2022-06-10
BR112019022483A2 (pt) 2020-05-12
GEP20257788B (en) 2025-08-25
US11123313B2 (en) 2021-09-21
US20210401777A1 (en) 2021-12-30
JP2023139000A (ja) 2023-10-03
NZ758564A (en) 2023-12-22
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
EP3615016A1 (en) 2020-03-04
KR20250145704A (ko) 2025-10-13
MY200172A (en) 2023-12-12
EP3615016A4 (en) 2021-02-24
PH12019502427A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
US20240189261A1 (en) Methods and compositions for treating sleep apnea
US20250186371A1 (en) Methods and compositions for treating sleep apnea
WO2020091862A1 (en) Methods and compositions for treating sleep apnea
OA19434A (en) Methods and compositions for treating sleep apnea.
HK40117857A (en) Methods and compositions for treating sleep apnea
EA045789B1 (ru) Способы и композиции для лечения апноэ во сне
HK40013951A (en) Methods and compositions for treating sleep apnea
HK40031779B (en) Methods and compositions for treating sleep apnea or simple snoring
HK40031779A (en) Methods and compositions for treating sleep apnea or simple snoring
EA047115B1 (ru) Способы и композиции для лечения апноэ сна

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)